Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of the National Cancer Institute

• Publication date

  1996-01-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JNCI/88.1.38PMID 8847724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-2 in cancer treatment: Disappointing or (still) promising? A review

  2005cited by this paper
• Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice.

  1995cited by this paper
• Role of interferon-gamma in mediating the antitumor efficacy of interleukin-12.

  1995cited by this paper
• Inhibition of angiogenesis in vivo by interleukin 12.

  1995cited by this paper
• Interleukin 12 (IL-12) induces tyrosine phosphorylation of JAK2 and TYK2: differential use of Janus family tyrosine kinases by IL-2 and IL- 12

  1995cited by this paper
• Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.

  1994cited by this paper
• Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12.

  1994cited by this paper
• Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

  1994cited by this paper
• Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms.

  1994cited by this paper
• In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS)

  1994cited by this paper
• Interleukin-12: A bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency

  1994cited by this paper
• Alterations in NF kappa B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy.

  1994cited by this paper
• Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells.

  1994cited by this paper
• Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis

  1994cited by this paper
• Interleukin‐12

  1994cited by this paper
• Lowest dose interleukin-2 immunotherapy.

  1993cited by this paper
• Recombinant interleukin 12 cures mice infected with Leishmania major

  1993cited by this paper
• Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells

  1993cited by this paper
• Antitumor and antimetastatic activity of interleukin 12 against murine tumors

  1993cited by this paper
• Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes.

  1993cited by this paper
• Interleukin‐12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells

  1993cited by this paper
• Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts.

  1993cited by this paper
• Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors.

  1993cited by this paper
• Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response

  1993cited by this paper
• Interleukin-2: its biology and clinical application in patients with cancer.

  1993cited by this paper
• Inhibition of angiogenesis.

  1992cited by this paper
• IL-12 receptor. II. Distribution and regulation of receptor expression.

  1992cited by this paper
• Cytokines and cytotoxic agents in renal cell carcinoma: a review.

  1992cited by this paper
• Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells.

  1992cited by this paper
• IL-12 augments antigen-dependent proliferation of activated T lymphocytes.

  1992cited by this paper
• Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).

  1991cited by this paper
• Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers

  1991cited by this paper
• Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells.

  1990cited by this paper
• Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro.

  1988cited by this paper
• Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.

  1988cited by this paper
• Synergy between recombinant interleukin 2 (rIL 2) and IL 2-depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocyte responses in vitro.

  1986cited by this paper
• Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

  1984cited by this paper
• Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues.

  1984cited by this paper
• Immunotherapy of a murine renal cancer.

  1983cited by this paper

• The role of cytokines in shaping the future of Cancer immunotherapy.

  2025cites this paper
• Multicolor Light-Induced Immune Activation via Polymer Photocaged Cytokines

  2022cites this paper
• Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy

  2021cites this paper
• Combination immunotherapy: a road map

  2017cites this paper
• Potency-matched Dual Cytokine–Antibody Fusion Proteins for Cancer Therapy

  2017cites this paper
• Combination immunotherapy: a road map The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

  2017cites this paper
• Oncolytic virotherapy with an armed vaccinia virus in an orthotopic model of renal carcinoma is associated with modification of the tumor microenvironment

  2015cites this paper
• The role of inflammation in kidney cancer.

  2014cites this paper
• SA-4-1BBL as a platform to develop adjuvant systems for prophylactic and therapeutic vaccines.

  2014cites this paper
• Targeted and Untargeted Fusion Proteins: Current Approaches to Cancer Immunotherapy

  2013cites this paper
• agonistic CD40 antibody administration transplant recipients from the lethal cytokine syndrome occurring after Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow

  2013cites this paper
• Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy

  2013cites this paper
• Apoptotic Potential of Cytokine Therapy for Proteasome Inhibition to Maximize the

  2013cites this paper
• Lethal NK-mediated inflammation induced by IL-12 in the absence of polymorphic and nonpolymorphic MHC class I molecules.

  2013cites this paper
• of an IL-12-Expressing Recombinant Adenovirus Hepatic Metastases by Systemic Administration T Cell- and NK Cell-Independent Inhibition of

  2013cites this paper
• Principles of psychoneuroendocrinoimmunotherapy of cancer.

  2012cites this paper
• IL-18 and IL-12 synergy induces matrix degrading enzymes in the lung

  2012cites this paper
• Delineation of antigen-specific and antigen-nonspecific CD8 (cid:1) memory T-cell responses after cytokine-based cancer immunotherapy

  2012cites this paper
• Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy.

  2012cites this paper
• Systemic IL-12 Administration Alters Hepatic Dendritic Cell Stimulation Capabilities

  2012cites this paper
• Experimental Animal Models for Investigating Renal Cell Carcinoma Pathogenesis and Preclinical Therapeutic Approaches

  2011cites this paper
• Proanthocyanidins Inhibit Photocarcinogenesis through Enhancement of DNA Repair and Xeroderma Pigmentosum Group A–Dependent Mechanism

  2010cites this paper
• Interleukin-18: biology and role in the immunotherapy of cancer.

  2010cites this paper
• Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy

  2010cites this paper
• Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow1

  2009cites this paper
• IL-12 deficiency suppresses 12-O-tetradecanoylphorbol-13-acetate-induced skin tumor development in 7,12-dimethylbenz(a)anthracene-initiated mouse skin through inhibition of inflammation.

  2009cites this paper
• Inhibition of UVB-induced skin tumor development by drinking green tea polyphenols is mediated through DNA repair and subsequent inhibition of inflammation.

  2009cites this paper
• Bone Marrow Neuroblastoma Metastases in the Liver and and Complete Regression of Disseminated Sensitization , Tumor-Specific CTL Reactivity IL-27 and IL-2 : Enhancement of T Cell Immunologic and Therapeutic Synergy of and

  2009cites this paper
• The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancer

  2008cites this paper
• Biological therapy for pediatric malignancy: Current perspectives

  2008cites this paper
• Chapter 38 – Primary Neoplasms of the Kidney

  2008cites this paper
• Antibody–cytokine fusion proteins: applications in cancer therapy

  2008influential citation
• Systemic Therapy for Metastatic Renal Cell Carcinoma: Cytokines

  2008cites this paper
• Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity

  2007cites this paper
• Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors

  2007cites this paper
• Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma.

  2007cites this paper
• Interleukin-12 and photocarcinogenesis.

  2007cites this paper
• Immunotherapy of cancer by IL-12-based cytokine combinations

  2007cites this paper
• Combination Therapy of an Orthotopic Renal Cell Carcinoma Model Using Intratumoral Vector-Mediated Costimulation and Systemic Interleukin-2

  2007cites this paper
• (-)-Epigallocatechin-3-gallate prevents photocarcinogenesis in mice through interleukin-12-dependent DNA repair.

  2006cites this paper
• Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.

  2006cites this paper
• Glucocorticoid amplifies IL‐2‐dependent expansion of functional FoxP3+CD4+CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAE

  2006cites this paper
• Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma.

  2006cites this paper
• Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors1

  2006cites this paper
• Interleukin-12-deficient mice are at greater risk of UV radiation–induced skin tumors and malignant transformation of papillomas to carcinomas

  2006cites this paper
• Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors

  2006cites this paper
• Neoadjuvant intratumoral cytokine‐loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti‐tumor immunity

  2006influential citation
• Novel Therapies for Renal Cell Cancer

  2005cites this paper
• Combination nonviral murine interleukin 2 and interleukin 12 gene therapy and radiotherapy for head and neck squamous cell carcinoma.

  2005influential citation
• Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.

  2005cites this paper
• Multiple testing procedures based on weighted Kaplan–Meier statistics for right‐censored survival data

  2005cites this paper
• Evaluation of the antitumor activity of interleukin-12 in an experimental murine model of colorectal cancer induced by 1,2 dimethyl-hydrazine (DMH).

  2005cites this paper
• Augmented human-tumor-cytolytic activity of peripheral blood lymphocytes and cells from a mixed lymphocyte/tumor culture activated by interleukin-12 plus interleukin-2, and the phenotypic characterization of the cells in patients with advanced carcinoma

  2005cites this paper
• Treatment of Relapsed and Refractory Neuroblastoma

  2005cites this paper
• Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice

  2005cites this paper
• Solid Tumors-role of biological agents in therapy

  2005cites this paper
• Alpha phenyl-tert-butyl nitrone (PBN) protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration.

  2004cites this paper
• IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells1

  2004cites this paper
• Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.

  2004cites this paper
• Serum Interleukin-12 Levels in Patients with Gastric Cancer

  2004cites this paper
• Interleukin 12 (IL-12) is increased in tumour bearing human liver and expands CD8(+) and CD56(+) T cells in vitro but not in vivo.

  2004cites this paper
• Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.

  2004cites this paper
• Immunotherapy for urological malignancies.

  2004cites this paper
• Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.

  2004cites this paper
• Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.

  2004cites this paper
• Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.

  2003cites this paper
• Targeting the lung: preclinical and comparative evaluation of anticancer aerosols in dogs with naturally occurring cancers.

  2003cites this paper
• Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression

  2003cites this paper
• Cell Responses + and CD8 CD40 and IL-2: Coordination of Dendritic Administration of Agonistic Antibodies to Synergistic Anti-Tumor Responses After

  2003cites this paper
• PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

  2003cites this paper
• Metastatic renal cell cancer treatments.

  2003cites this paper
• IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial

  2003cites this paper
• Novel Agents and Modalities for the Treatment of Squamous Carcinoma of the Head and Neck

  2003cites this paper
• Novel therapies for renal cell carcinoma – an update

  2003cites this paper
• Renal Cancer Treatment: A Review of the Literature

  2003cites this paper
• Phase I T rial o f C oncurrent T wice-Weekly R ecombinant Human I nterleukin-12 P lus L ow-Dose I L-2 i n P atients W ith Melanoma o r R enal C ell C arcinoma

  2003cites this paper
• Interleukin-2 and its receptor complex (α, β and γ chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study

  2003cites this paper
• Synergistic Anti-Tumor Responses After Administration of Agonistic Antibodies to CD40 and IL-2: Coordination of Dendritic and CD8+ Cell Responses 1

  2003cites this paper
• Immunomodulation in Established Murine Tumors

  2003cites this paper
• Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer

  2003cites this paper
• Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma.

  2003cites this paper
• Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.

  2003cites this paper
• Immunomodulation in established murine tumors: response and survival rate enhancement by blood leukocyte-augmenting substance 236 (Cl-), a novel synthetic compound.

  2003cites this paper
• PerforinTumor Regression In Vivo in the Absence of Ligand-Mediated Lysis In Vitro, But Cause Cancer Cells Using Both Perforin and Fas Tumor-Specific CTL Kill Murine Renal

  2002influential citation
• Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin1

  2002influential citation
• Combined Administration of IL-18 and IL-2 byFas-Ligand-Dependent Tumor Eradication and γ and Induction of IFN-Endogenous Anti-Tumor Immune Response Synergistic Engagement of an Ineffective

  2002cites this paper
• Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.

  2002cites this paper
• Interleukin-12 and interleukin-18 change ICAM-I expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells.

  2002cites this paper
• Synergistic Engagement of an Ineffective Endogenous Anti-Tumor Immune Response and Induction of IFN-γ and Fas-Ligand-Dependent Tumor Eradication by Combined Administration of IL-18 and IL-21

  2002cites this paper
• IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside

  2002cites this paper
• Immunotherapy of metastatic renal cell cancer.

  2002cites this paper
• Administration of either anti-CD40 or interleukin-12 following lethal total body irradiation induces acute lethal toxicity affecting the gut.

  2002cites this paper
• Combination interleukin-2 and interleukin-12 induces severe gastrointestinal toxicity and epithelial cell apoptosis in mice.

  2002cites this paper
• Clinical and Immunobiological Effects of Subcutaneous Recombinant Human Interleukin 12 in Patients with Metastatic Renal Cancer

  2002cites this paper
• Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity.

  2002cites this paper
• Experimental Animal Models for Renal Cell Carcinoma

  2002cites this paper
• Inhibitory effect of glycyrrhizin on experimental pulmonary metastasis in mice inoculated with B16 melanoma.

  2002cites this paper
• 4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner

  2002cites this paper
• Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.

  2002cites this paper
• CD8 T Cells in a CD40-Dependent Manner Immune Responses by Direct Activation of Promotes the Generation of Tumor-Specific 4-1BB-Specific Monoclonal Antibody

  2002cites this paper